Evidence map›Paper›PMID 39441632›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

Structure and function of

Delin Li, Xiaokang Zhang, Yuanhang Yao, Xue Sun, Junqing Sun, Xiaomin Ma, Kai Yuan, Guijie Bai, Xuefei Pang, Rongmao Hua and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Delin Li *Laboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.ORCID 0000-0002-7967-1581
Xiaokang Zhang *Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
Yuanhang Yao *College of Future Technology, Peking University, Beijing 100871, China.
Xue Sun *First School of Clinical Medicine, Peking University Health Science Center, Peking University, Beijing 100871, China.
Junqing SunShanxi Academy of Advanced Research and Innovation, Taiyuan 030032, China.
Xiaomin MaCryo-EM Center, Southern University of Science and Technology, Shenzhen 518055, China.ORCID 0009-0006-0458-5132
Kai YuanLaboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.
Guijie BaiLaboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.
Xuefei PangLaboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.
Rongmao HuaLaboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.
Tianling GuoLaboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.
Yuqian MiShanxi Academy of Advanced Research and Innovation, Taiyuan 030032, China.
Lingzhi WuCollege of Future Technology, Peking University, Beijing 100871, China.
Jie ZhangLaboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.
Yan WuDepartment of Pathogen Microbiology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China.ORCID 0000-0003-2734-0673
Yingxia LiuShenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen 518112, China.
Peiyi WangCryo-EM Center, Southern University of Science and Technology, Shenzhen 518055, China.ORCID 0000-0001-7737-181X
Catherine C L WongFirst School of Clinical Medicine, Peking University Health Science Center, Peking University, Beijing 100871, China.
Xiao-Wei ChenCollege of Future Technology, Peking University, Beijing 100871, China.ORCID 0000-0001-6466-6248
Haixia XiaoLaboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.ORCID 0000-0003-0032-5430
George Fu GaoLaboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.ORCID 0000-0002-3869-615X
Feng GaoLaboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.ORCID 0000-0002-0670-010X

Funding

China Postdoctoral Science Foundation (China Postdoctoral Foundation Project) 2019M660048Guangdong Basic and Applied Basic Research Foundation 2019A1515110675National Key R&D Program of China 2020YFA0907National Natural Science Foundation of China 82272379Tianjin Synthetic Biotechnology Innovation Capacity Improvement Project TSBICIP-KJGG-014
6 · The paper itself

Abstract

EfpA, the first major facilitator superfamily (MFS) protein identified in

Indexed as

Bacterial ProteinsCryoelectron MicroscopyMycobacterium tuberculosisBiological TransportMembrane Transport ProteinsModels, MolecularBacterial ProteinsMembrane Transport Proteinsdrug resistanceEfpAlipid transporterstructural basisTB

Identifiers

PMID39441632
PMCPMC11536138

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.